Rapport Therapeutics to Showcase Innovations in Epilepsy Research
Rapport Therapeutics to Showcase Innovations in Epilepsy Research
Rapport Therapeutics, Inc. (Nasdaq: RAPP), a pioneering clinical-stage biotechnology firm, is excited to announce its participation at the upcoming American Epilepsy Society Annual Meeting. This prestigious event will unfold from December 6-10, bringing together experts dedicated to improving treatments for those battling central nervous system (CNS) disorders.
Key Presentations at the American Epilepsy Society Annual Meeting
At this meeting, Rapport will unveil critical data derived from a long-term treatment study involving the RNS® System. This research seeks to define the relationship between a notable decrease in long episode (LE) frequency—marked as abnormal electrographic activity—and a meaningful reduction (50%) in seizures reported by patients. This LE biomarker is pivotal in the ongoing Phase 2a proof-of-concept trial for the company's lead therapeutic candidate, RAP-219, envisioned as an innovative approach to treat drug-resistant focal epilepsy.
Overview of the Phase 2a Trial
The Phase 2a trial focuses on the frequency of long episodes in individuals using the RNS® System. This responsive neurostimulation device has shown promise in reducing the frequency of clinical seizures. By examining the anxieties and needs of those living with epilepsy, the team at Rapport Therapeutics aims to establish a new standard in managing seizures and improving patients' quality of life.
Featured Research Posters and Presentations
Rapport will display an array of posters highlighting their findings, including:
Poster Titles and Presenters
1. **Antiseizure Effects with Selective TARP?8 Negative Allosteric Modulators in Preclinical Seizure Models** (Poster #390)
**Presenters:** Jose Matta, PhD; Brock Shireman, PhD; Laurie Volak, PhD; Michael Maher, PhD; David Bredt, MD, PhD
2. **Impact of Food on the PK and Tolerability of RAP-219 in Healthy Volunteers** (Poster #409)
**Presenters:** Stephen Greene, PharmD; Swamy Yeleswaram, PhD
3. **Optimal Cut Point for Reduction in Long Episode Frequency to Predict Meaningful Change in Clinical Seizure Frequency** (Poster #494)
**Presenters:** Arnold R Gammaitoni, PharmD, et al.
4. **Safety, Tolerability, and Pharmacokinetics of RAP-219 in Healthy Volunteers** (Poster #372)
**Presenters:** Swamy Yeleswaram, PhD; Bradley Galer, MD; William Motley, MD; Stephen Greene, PharmD
Mark Your Calendars for the Scientific Exhibit Room
On December 9, 2024, from 2:00 p.m. to 5:00 p.m. PST, Rapport will host a scientific exhibit showcasing the above posters along with:
- The evolution of RAP-219 in epilepsy treatment
- A novel design for a focal epilepsy proof-of-concept trial
- Details on how RAP-219 acts as a negative allosteric modulator of TARP?8
About RAP-219: A New Hope for Epilepsy Treatment
RAP-219 is a groundbreaking clinical-stage AMPAR negative allosteric modulator targeting TARP?8. By focusing on areas in the brain with specific receptor expressions, this medication aims to provide notable clinical efficacy while minimizing undesirable side effects. Rapport believes that its novel approach not only sets a new bar for treatment but also reflects a crucial step toward offering sustained therapeutic solutions for patients with diverse neurological disorders.
The Vision of Rapport Therapeutics
Rapport Therapeutics has pushed the boundaries of conventional drug discovery. The company's founders have made significant strides in understanding receptor-associated proteins, forming the base of their innovative technology platform. Through this, Rapport is generating targeted therapies intended to transform how patients experience and manage CNS disorders.
Frequently Asked Questions
What is the American Epilepsy Society Annual Meeting?
The American Epilepsy Society Annual Meeting is a gathering of experts and researchers focused on advancements in epilepsy research and patient care.
What is RAP-219?
RAP-219 is a clinical-stage therapy designed to treat drug-resistant focal epilepsy through the modulation of AMPARs in specific brain regions.
When will the presentations take place?
The presentations will occur from December 6-10, 2024, at the American Epilepsy Society Annual Meeting.
Who is presenting for Rapport Therapeutics?
A talented team of researchers, including PhDs and MDs, will present findings related to RAP-219 and its clinical studies.
How can I find out more about Rapport Therapeutics?
For more information, please contact Rapport Therapeutics directly or visit their official website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.